Business Wire

FlexTrade Implements Machine Learning for Real-time Market Impact Analytics

11.5.2022 11:14:00 EEST | Business Wire | Press release

Share

FlexTrade Systems, a global leader in multi-asset execution and order management systems, today announced the launch of machine-learning driven real-time market impact analytics, which are now available within FlexTRADER EMS.

This analytics enhancement comes as the industry calls for solutions providers to increase innovation and deliver actionable analytics to help improve decision-making and reduce market impact on the buy-side trading desk. FlexTrade's in-house data science team has driven the new initiative and refined it further through input and collaboration with clients.

FlexTrade's market impact analytics are generated by applying a proprietary neural network model to a large corpus of order data to help investment managers understand the performance of their execution strategies. The solution allows traders to see an estimate of their current and realized market impact in real-time, meaning strategies can be monitored and adjusted automatically based on market conditions. Traders using the solution can also leverage data visualization to understand how the market impact has changed over the life of the order, including any increases or decreases as more volume is traded or when an order is finished or paused. Further, the new offering, deeply integrated directly within the FlexTRADER EMS order blotter, can be viewed holistically alongside third-party analytics to deliver increased transparency, improved trading decision-making and assist with best execution obligations.

FlexTrade's real-time machine-learning driven market impact analytics are available immediately for deployment, with the first client, an EMEA based Tier 1 buy-side asset manager, live in production. FlexTrade will showcase the new analytics offering this month at WBR's TradeTech Europe in Paris on the 11th and 12th of May.

Andy Mahoney, Managing Director, EMEA at FlexTrade, noted : "Designing and delivering ground-breaking innovation is at the core of what we do at FlexTrade. Leveraging new technologies such as machine learning ensures FlexTrade's clients can take advantage of unique, actionable insights to drive their trading in real-time. At a time when the industry is calling for innovation to return following a lull, understandably, caused by the pandemic, we are at the front of the pack offering disruptive technologies led initiatives - rapidly delivered to the market and our clients - that add real tangible value to their execution strategies."

About FlexTrade

Founded in 1996, FlexTrade Systems is the global leader in high performance execution management and order management systems for equities, foreign exchange, options, futures, and fixed income.

A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER, the world's first broker-neutral, and execution management trading system, which allows clients to completely control and customize their proprietary algorithms while maintaining the confidentiality of their trading strategies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Iain Smith
Iain.Smith@FlexTrade.com
o: +44 20 3757 9311 x 9311

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Multi-Color Corporation Receives Court Approval of First Day Motions4.2.2026 22:30:00 EET | Press release

Multi-Color Corporation (“MCC” or the “Company”), a global leader in prime label solutions, today announced that it has received approval from the U.S. Bankruptcy Court for the District of New Jersey (the “Court”) for first day relief related to its prepackaged Chapter 11 filed on January 29, 2026. The approved relief affirms that the Company will operate in the normal course, pay all trade vendors and suppliers in full, and maintain a strong liquidity position during the restructuring. As part of this relief, the Court granted MCC immediate access to $125 million of $250 million in debtor-in-possession (“DIP”) new money financing, provided by certain holders of MCC’s secured first lien debt and its equity sponsor, CD&R. This funding will capitalize the business through the initial stages of the prepackaged Chapter 11 process. The Court also granted MCC authority to pay trade vendors and suppliers in full in the ordinary course, maintain wages and benefits without interruption, satisfy

InterSystems Honored with Four 2026 Best in KLAS Awards4.2.2026 19:00:00 EET | Press release

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has received four Global 2026 Best in KLAS awards. The company earned a #1 ranking for Acute Care EHR in Asia, Oceania, and France, as well as for Shared Care Records in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204241673/en/ InterSystems earns four Best in KLAS awards for 2026 Best in KLAS is KLAS Research’s annual recognition of top-performing healthcare technology and services solutions, based entirely on feedback from healthcare provider organizations. Awards are given within defined software and services market segments evaluated by KLAS Research using a standardized methodology that reflects customer experience and performance. In addition to U.S. market segments, KLAS also recognizes top-performing solutions through its Global (Non-U.S.) Best in KLAS Awards, which are based on fe

Onego Bio Strengthens Board with Appointment of Dr. Antti Vasara4.2.2026 17:00:00 EET | Press release

Onego Bio, the food ingredient company producing non-animal egg protein through precision fermentation, today announced that Dr. Antti Vasara has joined its board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260204881159/en/ Dr. Antti Vasara Dr. Vasara brings more than 25 years of global experience in science, technology, and commercial strategy. Most recently, he served as President and CEO of VTT Technical Research Centre of Finland, where he led one of Europe’s foremost deep tech research organizations. His distinguished career spans senior leadership roles in industry and innovation policy—including impactful work with Nokia and strategic contributions to European research and development initiatives. “Antti is one of the most respected leaders in science and innovation,” said Maija Itkonen, CEO of Onego Bio. “His deep understanding of technology commercialization and ecosystem level strategy will be inva

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye